Press Releases

FUJIFILM PRESENTS INTEGRATED SYNAPSE PORTFOLIO TO OPTIMIZE WORKFLOW AND IMPROVE PATIENT CARE AT ACC 2014 Stamford, Conn., March 27, 2014 (Booth #2921 - Hall B) –FUJIFILM Medical Systems U.S.A., Inc. will highlight an integrated Synapse portfolio that allows cardiologists  and clinical professionals to enhance patient care through optimized productivity at the 63rd Annual Scientific Session & Expo of the American College of Cardiology (ACC) on March 29 - 31 in Washington, DC.  “Cardiology departments need solutions that will improve workflow. Fujifilm offers advanced features and exceptional images to accelerate workflow and enhance diagnostic confidence,” said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical Systems U.S.A., Inc. “With Synapse, our customers are able to perform their job more efficiently and ultimately allows them to concentrate more on the patient and improve overall patient outcomes.” Following is a summary of offerings:Synapse Cardiovascular helps cardiologists in a variety of clinical areas efficiently and confidently interpret exceptional images with streamlined workflow, image review and reporting. With full image management and reporting capabilities, and tools designed specifically for nuclear cardiology, vascular ultrasound, ECG management, echocardiography, cardiac catheterization, CT, and Cardiac MRI workflows, Fujifilm's Synapse Cardiovascular is an essential addition to any clinical workplace. Cardiologists interested in advanced visualization and analysis will find the innovations of Fujifilm’s Synapse 3D very appealing for their diagnostic needs with twenty nine functions to choose from. It is fully integrated with Synapse PACS and Synapse Cardiovascular, and eliminates the need to access advanced diagnostic tools from a separate workstation or with a separate login. Patient lists are synchronized, making it up to date at all times. Also to be introduced is Synapse Analytics, an advanced tool that provides critical, timely data to assist decisions made by healthcare professionals about clinical operations and financial performance. This is a single application for use across the Synapse PACs, RIS, and CV platforms and allows the user to build, manipulate, and monitor a full suite of Business Intelligence dashboards and reports. To register for a product demonstration at ACC, please visit: http://www.fujimed.com/gateway/acc/2014/pacs.asp . For more information about Synapse, please visit: http://cardiovascular.fujimed.com/  About Fujifilm FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com  and www.fujifilmendoscopy.com .

FUJIFILM PRESENTS LATEST HEALTHCARE IT TECHNOLOGIES AT 2014 SOCIETY FOR IMAGING INFORMATICS IN MEDICINE (SIIM) Stamford, Conn., May 12, 2014 (Booth #330-334) – FUJIFILM Medical Systems U.S.A., Inc., will present its comprehensive Synapse portfolio for IT professionals at the 2014 annual meeting of the Society for Imaging Informatics in Medicine (SIIM) in Long Beach, California from May 15-17, 2014. The Synapse family of products combined provides management of the complete patient record, ensuring diagnostic integrity while providing fast, secure access to clinical users via web platforms or mobile devices. “Integration of all imaging types and formats with the EMR from a centralized repository is rapidly underway,” said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical Systems U.S.A., Inc. “This trend has led to the adoption of Synapse VNA and Mobility in some of the largest hospital networks in the country.” Visit SIIM booth #330-334 to learn more about Fujifilm’s offerings through live demonstrations and opportunities for face-to-face conversations. Following is a summary of offerings: The cornerstone of Fujifilm’s integrated solution is Synapse PACS. Two main goals – enhanced communication and optimized productivity for radiologists in any imaging environment – were the impetus behind its development.  The next generation of Synapse RIS, the most advanced Radiology Information System on the market today, will also be shown. Synapse RIS and PACS integrate seamlessly, allowing the radiologist to see scanned documents and history from within the PACS, and allowing the user to see images from within the RIS. The system has also received EHR certification, enabling it to be part of the Meaningful Use initiative that provides financial incentives to medical professionals who use a certified EHR.   Fujifilm has also announced the integration of vendor neutral architecture (VNA) into its Synapse portfolio. Synapse VNA provides the platform to interface and integrate the data generated by these systems, and provide actionable intelligence. Synapse VNA will enhance image management, streamline workflow, reduce costs and, most importantly, improve patient care. It can be implemented within any environment and offers data access and availability.  The archive allows sharing and consolidation of the storage and provides secure access across all authorized users.   Synapse VNA provides a unified viewing experience for the VNA DICOM and non-DICOM data. The Synapse VNA solution also embraces the importance of fast access to content through a zero download single viewing solution capable by displaying any content within the VNA securely to any desktop, mobile device, or through EMR with Synapse Mobility. For more information visit: www.fujimed.com.

Superb micro-vascular imaging helps clinicians deliver a more accurate diagnosis. Toshiba is making it possible for clinicians to use ultrasound to see the smallest vessels in and around areas like tumors and lymph nodes, giving them a new way to diagnose disease faster and non-invasively.

SAN ANTONIO, July 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received combined clearances from the U.S. Food and Drug Administration (FDA) that will enable IBA to market-launch the Proton Therapy specific Cone Beam Computed Tomography (CBCT) solution.

MINNEAPOLIS and SEATTLE — (July 29, 2014) vRad (Virtual Radiologic) the largest U.S. telemedicine company and radiology practice with over 450 physicians, and Remote Medical International® (RMI), a leading provider of global medical support services for remote locations, announced today that vRad is providing 24x7 emergent teleradiology services for RMI’s medical staff supporting the U.S. Military in Afghanistan and Kuwait.

Based on its recent analysis of the breast imaging systems market, Frost and Sullivan recognizes Gamma Medica with the 2014 Global Frost and Sullivan Award for Product Leadership.

UltraSpect, provider of the only multi-vendor and most cost-effective imaging solution for meeting the American Society of Nuclear Cardiology (ASNC) low dose guidelines, announces today that Henry Ford Wyandotte Hospital in Michigan has upgraded its nuclear medicine (NM) image reconstruction software to UltraSpect Xpress3.Cardiac. As a result, all patients receiving NM exams now have exams in half the time, with half the dose, regardless of the model or age of camera being used.

Lantheus Holdings, parent company to Lantheus Medical Imaging, a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol "LNTH." The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

 FUJIFILM MEDICAL SYSTEMS U.S.A., INC. DEMONSTRATES LATEST INNOVATIONS IN ECHOCARDIOGRAPHY IMAGE MANAGEMENT AND REPORTING AT THE 25th ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY Stamford, Conn., June 19, 2014 (Booth #301) – FUJIFILM Medical Systems U.S.A., Inc. will demonstrate the next generation of Synapse Cardiovascular, that will allow cardiologists and clinical professionals to enhance patient care through advanced reporting applications  at the 25th Annual Scientific Session of the American Society of Echocardiography in Portland, Oregon. “With Synapse, our users are able to perform their job more efficiently and ultimately allow them to concentrate more on the patient and improve patient outcomes,” said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical Systems U.S.A., Inc. “At ASE, we will demonstrate an upcoming clinical reporting platform that will feature a new user interface and layout options that has the potential to benefit your entire practice.” Following is a summary of offerings:Synapse Cardiovascular helps cardiologists in a variety of clinical areas efficiently and confidently interpret images and compose structured reports with a streamlined workflow. The system has powerful capabilities designed specifically for, echocardiography, cardiac catheterization and invasive peripheral vascular, nuclear cardiology, vascular ultrasound, ECG management, CT, and Cardiac MRI workflows. Fujifilm's Synapse Cardiovascular is an essential addition to any clinical workplace.  At the show, attendees will also be able to see a works-in-progress demonstration of Synapse Cardiovascular 6.0*, which will showcase intended future functionality for echocardiography. Fujifilm will also share the benefits of its zero footprint mobile application, Synapse Mobility. The application enables access to Fujifilm’s suite of Synapse products from hand-held devices, in addition to browser independence. Access to non-DICOM information from the Synapse VNA has been added to complete the universal viewing capability from EMRs such as Epic Hyperspace.  Synapse Mobility continues to demonstrate its diagnostic capability for both browser and mobile versions. To register for a demonstration at ASE 2014, please visit: http://www.fujimed.com/gateway/ase/2014/registration.html.  *Synapse Cardiovascular 6.0 will be made commercially available in the U.S. upon receipt of FDA clearance For more information about Synapse, please visit: http://cardiovascular.fujimed.com/

Together, the American Society for Radiation Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM) will share details about RO-ILS: Radiation Oncology Incident Learning System, a new, national patient safety initiative to facilitate safer and higher quality radiation oncology care.

During the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation, helping physicians deliver the best possible patient outcomes.

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.

The Interactive Patient Profiler for AdreView is a simulation tool designed to help educate physicians on the use of AdreView (Iobenguane I 123 Injection) to assess mortality risk in patients with heart failure. The tool demonstrates the types of patients where the use of AdreView can provide further information to assist physicians in identifying patients who may have a lower one- and two-year mortality risk, among groups of patients with similar profiles based on other clinical information.

Piramal Imaging released details from research presented at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), currently underway at St. Louis Convention Center in St. Louis, Mo.

NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through NorthStar’s unique intelligent isotope separation systems, once that technology is approved by the FDA and commercially available.

Royal Philips today introduced Vereos PET/CT, the first digital PET/CT scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging  (SNMMI), taking place this week in St. Louis, Mo.  In addition to Vereos, Philips will showcase a selection of innovative, molecular imaging solutions designed to deliver outstanding image quality, critical clinical information and greater connectivity.

ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand the clinical development of this promising imaging agent in the US and internationally.

Bethesda, MD (June 3, 2014) The American Society of Nuclear Cardiology (ASNC) will be offering a Nuclear Cardiology Board Exam Preparation Course from July 11-13 at the Intercontinental Hotel Chicago O'hare in Rosemont, Ill.

The University of Minnesota Medical Center – Fairview Health Services, Minneapolis, recently became the first U.S. health care facility to install the Symbia Intevo xSPECT system from Siemens Healthcare.

A U-SPECT+/CT (MILabs, The Netherlands) will be installed at Northwestern University (Chicago, IL) to deliver ultra-high resolution, high sensitivity, accurate quantification and fast scanning speed of dynamic radio-labeled molecule distributions, contributing to molecular and functional studies in CNS, cardiovascular, oncology, nephrology and reproductive biology.